Sygnature Discovery – High content iPSC-derived microglia inflammatory model

The High-Content Microglia Inflammatory Model Poster from Axol Bioscience and Sygnature Discovery presents a robust and scalable in vitro platform for studying neuroinflammation using human iPSC-derived microglia (iMGL). These models enable kinetic and endpoint phagocytosis assays, multiplexed imaging, and patient-specific disease modeling.

Key highlights include:

• Axol iPSC-Derived Microglia (axoCells™ iMGL): Cultured in 384-well plates, expressing key markers TMEM119 and P2RY12, and demonstrating functional phagocytosis of Aβ1-42.
• Live Cell Phagocytosis Assay: Uses pHrodo®-labeled Aβ1-42 peptide to track uptake in acidic lysosomes; inhibited by cytoskeletal disruptors like cytochalasin D.
• Endpoint Phenotypic Assay: High-resolution imaging of Aβ1-42 co-localization with LAMP1; quantifies % phagocytic cells and subcellular distribution.
• TREM2 Mutation Modeling: Patient-derived iMGL with TREM2 W50C mutation show reduced phagocytosis compared to healthy controls, validated via kinetic and endpoint assays.
• Multiplexed Imaging: Simultaneous visualization of nuclei, Aβ1-42, TREM2, LAMP1, and cell health using MetaXpress® software.
• Automation Ready: Compatible with acoustic dispensing and digital tracking for scalable drug screening.

This model supports early-stage CNS drug discovery, enabling pharmacological profiling of compounds targeting neuroinflammation and Alzheimer’s disease.

Featured Axol Products:

• axoCells™ iPSC-Derived Microglia (iMGL) – Terminally differentiated microglia for inflammation and phagocytosis assays
• axoCells™ Media & Supplements – Optimized reagents for microglia culture and functional assays
• Custom iPSC Lines – Including TREM2 LoF mutation donors for disease modeling